A semiconductor chip detects antigen concentrations at 1 parts per quadrillion molar mass

December 01, 2020

Overview: Associate Professor Kazuhiro Takahashi and Assistant Professor Yong-Joon Choi of the Department of Electrical and Electronic Information Engineering at Toyohashi University of Technology have developed a chip that can sense antigens at one part per quadrillion molar mass. The chip was created using semiconductor micromachining technology. Antigens derived from diseases and present in blood and saliva were adhered onto the surface of a flexibly deformable nanosheet. The amount of force generated during the interaction between adhered antigens was then converted into nanosheet deformation information in order to successfully detect specific antigens. Created with semiconductor technology machined at the millimeter scale, this sensor chip is expected to contribute to telemedicine by functioning as an IoT biosensor that allows antigen and antibody tests to be carried out from home.

Details: The measuring device simply and quickly detects diseases using a minuscule amount of blood, urine, saliva, or other bodily fluid, and will be a vital tool for accurately diagnosing diseases, verifying treatment results, and checking for recurrences and metastasis. Research is being conducted into a biosensor that can measure treatment results and pathological reactions by detecting DNA, RNA and proteins contained in such fluid. This technology has recently attracted interest across the globe, with antigen and antibody detection widely used to detect and determine the presence of novel coronavirus infections. Furthermore, among COVID-19 patients, reports suggest that patients with severe symptoms show differences in multiple protein concentrations contained in the blood when compared to those with mild symptoms. By examining such markers, this technology is expected to be used to predict illness severity. Current detection devices are not digitalized, and require visual confirmation of color changes using a labeling agent. Reading the wide range of markers is time consuming, and has made implementation for IoT devices difficult. The research team is developing a micro sensor chip that checks for diseases using a flexibly deformable nanosheet made using semiconductor micromachining technology. First, an antibody that catches the targeted antigens is fixed onto the nanosheet, and deformations to a thin film caused by electric repulsions among the adhered antigens is measured. To improve sensitivity to the point where the membrane that the antigens adhere to becomes thin and soft, organic nanosheets two-times softer than semiconductor silicon are used. This is expected to improve sensor sensitivity to a magnitude twice that of conventional silicon-based sensors. In addition, development is continuing on signal detection technology that uses a smartphone camera to detect nanosheet deformation.

With this sensor, which is designed for sensitive changes in adhesion of biomolecules, the antibody must be fixed to the nanosheet in advance in order to capture the antigen, and issues related to film degradation can make this process difficult. The research team optimized density for antibodies to adhere to a nano membrane with adjustable thickness, creating a biosensor that detects only antigens with specifically high sensitivity. Moreover, since it is possible to detect deformation to the nano sheet caused by adhered molecules in real time, the technology is expected to allow for quick detection of disease-derived molecules. The biosensor developed in this project was used in an experiment to detect albumin, a protein contained in blood. The experiment successfully detected one femtogram (15 attomoles in molar concentration) of antigen contained in one milliliter. With the minimum detection limit almost equivalent to that of large-scale detection devices that use labeling agents, this device is expected to allow for ultra-sensitive detection on a portable scale.

Future Outlook: Going forward, the research team plans to conduct trials using semiconductor sensors to detect markers for severe symptoms of COVID-19 infection. In addition to blood detection, chemical sensors are being developed to detect odor and chemical substances. We believe we can contribute to an IoT-based society by making new, small-scale sensor devices a reality. Replacing the probe molecule on the surface of our nanosheet, the technology can be used to detect viruses while also detecting a variety of biomarkers. By making these biosensors common in society, we aim to contribute to telemedicine, allowing doctor diagnoses to be performed from home.
-end-
Reference: Yong-Joon Choi, Toshiaki Takahashi, Miki Taki, Kazuaki Sawada, and Kazuhiro Takahashi, Label-free attomolar protein detection using a MEMS optical interferometric surface-stress immunosensor with a freestanding PMMA/parylene-C nanosheet, Biosensors and Bioelectronics, DOI: 10.1016/j.bios.2020.112778

This research was conducted with grants from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) Scientific Research Fund (Basic Research (B)), the Japan Science and Technology Agency (JST) PRESTO Creation of Innovative Nanoelectronics Combining Materials, Devices, and Systems, and a Future Challenge 2050 grant from the New Energy and Industrial Technology Development Organization (NEDO).

Toyohashi University of Technology (TUT)

Related Antibody Articles from Brightsurf:

Antibody evolution may predict COVID-19 outcomes
For COVID-19, the difference between surviving and not surviving severe disease may be due to the quality, not the quantity, of the patients' antibody development and response, suggests a new study.

Can an antibody 'cocktail' prevent COVID-19 infection?
In a new COVID-19 clinical trial, Stuart Cohen at UC Davis Health tests monoclonal antibody combination to prevent COVID-19 in adults exposed to infected patients.

An in-depth analysis of antibody responses to SARS-CoV-2
Using a technology called VirScan to study coronavirus antibody responses in a large cohort of SARS-CoV-2-infected and control individuals, researchers identified epitopes recognized by a large fraction of COVID-19 patients, epitopes cross-reactive with antibodies developed in response to other human coronaviruses, and 10 epitopes likely recognized by neutralizing antibodies.

Tracking antibody profiles for influenza exposures across the lifespan
Immune responses to influenza exposures increase early in life, then decline in middle age, according to a study published July 23 in the open-access journal PLOS Pathogens by Bingyi Yang of the University of Florida, Steven Riley of Imperial College London, Derek Cummings of the University of Florida, and colleagues.

New study ranks performance of currently available COVID-19 antibody tests
Conducted by researchers at NSF International and Novateur Ventures, the peer-reviewed study finds significant variability in the accuracy of available COVID-19 antibody tests.

Ushering an antibody cocktail, designed to reduce antibody resistance, to trial as COVID-19 therapy
Following two studies that screened thousands of human antibodies to SARS-CoV-2 to identify highly potent pairs, in which the antibodies bind non-overlapping regions of the viral target, a resultant antibody cocktail is being tested in human trials.

COVID-19 antibody tests: How reliable are they?
With stay-at-home orders expiring around the world, many hope that COVID-19 antibody testing will help businesses and institutions reopen safely.

A faster way to make antibody-drug conjugates
In a study published today in Science Advances, USC scientists describe a new technology to rapidly create a homogeneous type of ADC, which attaches to a specific site on the cancer cell, with improved efficiency and potentially enhanced stability, effectiveness and safety.

Antibody designed to recognize pathogens of Alzheimer's disease
Researchers have found a way to design an antibody that can identify the toxic particles that destroy healthy brain cells -- a potential advance in the fight against Alzheimer's disease.

New technology can detect anti-virus antibody in 20 minutes
Researchers have succeeded in detecting anti-avian influenza virus antibody in blood serum within 20 minutes, using a portable analyzer they have developed to conduct rapid on-site bio tests.

Read More: Antibody News and Antibody Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.